More than 200 oncologists worldwide now involved in assessment and selection of potential treatments LONDON–(BUSINESS WIRE)–Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses now has more than … [Read more…]
Financing will accelerate commercial roll-out of the company’s cloud-based platform that provides a unified workspace for data-intensive biomedical research accessible by both biologists and bioinformaticians CAMBRIDGE, Mass.–(BUSINESS WIRE)–#bioinformatics–Watershed Informatics, developer of a multi-omics insight platform for biopharmaceutical discovery teams, today announced the closing of a $14.5M Series A financing led by Canvas Ventures, with participation … [Read more…]
BELOIT, Wis.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be presenting at the upcoming Jefferies Radiopharma Innovation Summit. The event will be held in New York, NY, on April 3, 2023. Stephen Merrick, Chief Executive … [Read more…]
HOUSTON–(BUSINESS WIRE)–Lightning Step has announced a partnership with CHESS Health, the leading provider of evidence-based digital health solutions for substance use disorder (SUD), which will allow clients to seamlessly connect at intake or discharge to online tools that will help them stay in treatment and recovery. Through a free one-click add-on, Lightning Step will be … [Read more…]
Inaugural Event on June 29, 2023, at the Sanford Consortium for Regenerative Medicine CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality … [Read more…]
CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris will … [Read more…]
Top-Line Results Expected in the First Half of 2023 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of the orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of chronic cough. The multicenter, randomized, double-blind, placebo-controlled, two-period Phase 2 crossover … [Read more…]
Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 200 basis points year over year GAAP loss per share of $0.24 and adjusted … [Read more…]
Pryor will spearhead BeiGene’s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor … [Read more…]
−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus 10% Receiving Placebo.1 −Superiority over Placebo Was Also Demonstrated at Week 34, with 35% of Vedolizumab Patients Achieving Remission Compared with 18% on Placebo.1 OSAKA, Japan … [Read more…]
